Literature DB >> 21150581

A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants.

William L Hickerson1, Israel Nur, Roberto Meidler.   

Abstract

The objective of the present study was to compare the mechanical, kinetic, and biochemical properties of fibrin clots produced using EVICEL Fibrin Sealant (Human) and TISSEEL Fibrin Sealant. The stiffness/elasticity and strength of fibrin clots formed with EVICEL and TISSEEL were assessed using applied mechanical force and thromboelastography (TEG). The factor XIII content of the fibrin clots was also evaluated. Mean Young modulus and tensile strength of the fibrin clots produced by EVICEL were significantly higher than those of clots produced by TISSEEL (P < 0.05 for both). The mean time to initial clot formation and mean time to the predefined level of clot formation were numerically shorter for EVICEL compared with TISSEEL. Furthermore, mean maximal amplitude of the clots formed with EVICEL was significantly greater than that for the clots formed with TISSEEL. Mean concentration of factor XIII for the EVICEL fibrinogen samples tested was 9 IU/ml compared with undetectable concentrations of factor XIII for the TISSEEL fibrinogen samples. Fibrin clots formed with EVICEL have a much higher resistance to stretching and tensile strength and are more capable of maintaining their structure against applied force than those formed with TISSEEL. EVICEL also allows more rapid development of fibrin clots than TISSEEL. This superior clot strength and resilience obtained with EVICEL relative to TISSEEL may be due in large part to the presence of factor XIII.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21150581     DOI: 10.1097/MBC.0b013e32833fcbfb

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  17 in total

1.  Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications.

Authors:  Kassandra S Thomson; F Steven Korte; Cecilia M Giachelli; Buddy D Ratner; Michael Regnier; Marta Scatena
Journal:  Tissue Eng Part A       Date:  2013-01-14       Impact factor: 3.845

Review 2.  Fibrin sealant (evicel® [quixil®/crosseal™]): a review of its use as supportive treatment for haemostasis in surgery.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

3.  Histologic evaluation of absorbable and non-absorbable barrier coated mesh secured to the peritoneum with fibrin sealant in a New Zealand white rabbit model.

Authors:  E D Jenkins; L Melman; S Desai; C R Deeken; S C Greco; M M Frisella; B D Matthews
Journal:  Hernia       Date:  2011-05-24       Impact factor: 4.739

Review 4.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

Review 5.  Fibrin mechanical properties and their structural origins.

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Matrix Biol       Date:  2016-08-20       Impact factor: 11.583

6.  Surgical Materials: Current Challenges and Nano-enabled Solutions.

Authors:  Nasim Annabi; Ali Tamayol; Su Ryon Shin; Amir M Ghaemmaghami; Nicholas A Peppas; Ali Khademhosseini
Journal:  Nano Today       Date:  2014-10-01       Impact factor: 20.722

7.  Prevention of postoperative anemia in hip hemiarthroplasty for femoral neck fractures: comparison between local haemostatic agents.

Authors:  Antonio Ziranu; Cesare Meschini; Davide De Marco; Giuseppe Sircana; Maria Serena Oliva; Giusepp Rovere; Andrea Corbingi; Raffaele Vitiello; Giulio Maccauro; Enrico Pola
Journal:  Orthop Rev (Pavia)       Date:  2022-10-13

8.  Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.

Authors:  Juli R Bagó; Guillaume J Pegna; Onyi Okolie; Shawn D Hingtgen
Journal:  Biomaterials       Date:  2016-01-06       Impact factor: 12.479

9.  Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses.

Authors:  Kassandra S Thomson; Sarah K Dupras; Charles E Murry; Marta Scatena; Michael Regnier
Journal:  Angiogenesis       Date:  2013-10-15       Impact factor: 9.596

10.  Transurethral Use of Evicel(®) Fibrin Sealant.

Authors:  Jonathan L Masel
Journal:  Urol Case Rep       Date:  2015-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.